Health Economics of Use Fluoroquinolones to Treat Patients with Community-Acquired Pneumonia

American Journal of Medicine

Volumn 123, Issue 4 SUPPL., 2010, Pages

  Restrepo, Marcos I ^a,b   Frei, Christopher R ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Lactams; Fluoroquinolones; Macrolides; Medical economics; Respiratory disorders

Indexed keywords

AZITHROMYCIN; BETA LACTAM; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CLARITHROMYCIN; ERYTHROMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; HEALTH ECONOMICS; HOSPITAL COST; HOSPITAL RUNNING COST; HUMAN; LENGTH OF STAY; MEDICAL DECISION MAKING; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG COSTS; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MACROLIDES; PNEUMONIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 77949881627     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.02.005     Document Type: Article

References (52)

1. Cunha B.A. Principles of antibiotic formulary selection for P&T committees. Part 5: the cost of antimicrobial therapy. Pharm Ther 28 (2003) 662-665
2. Hoffman J.M., Shah N.D., Hunkler R.F., Hontz K.M., and Vermeulen L.C. Projecting future drug expenditures-2004. Am J Health Syst Pharm 61 (2004) 145-158
3. Hoffman J.M., Shah N.D., Vermeulen L.C., et al. Projecting future drug expenditures-2007. Am J Health Syst Pharm 64 (2007) 298-314
4. Niederman M.S., McCombs J.S., Unger A.N., Kumar A., and Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 20 (1998) 820-837
5. Nicolau D.P. The challenge of prescribing treatment for respiratory tract infections. Am J Manag Care 69 suppl (2000) S419-S426
6. Dresser L.D., Niederman M.S., and Paladino J.A. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 119 (2001) 1439-1448
7. Orrick J.J., Segal R., Johns T.E., Russell W., Wang F., and Yin D.D. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics 22 (2004) 751-757
8. Frei C.R., and Burgess D.S. Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia. Formulary 40 (2005) 298-303
9. Sun H.K., Nicolau D.P., and Kuti J.L. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest 130 (2006) 807-814
10. Centers for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group. The nation's health dollar, calendar year 2007: where it went [pie chart]. [CMS Website.]. http://www.cms.hhs.gov/NationalHealthExpendData/downloads/PieChartSourcesExpenditures2007.pdf Accessed April 17, 2009
11. DeFrances C.J., Lucas C.A., Buie V.C., and Golosinskiy A. 2006 national hospital discharge survey. Natl Health Stat Report (2008) 1-20
12. Kung H.C., Hoyert D.L., Xu J., and Murphy S.L. Deaths: final data for 2005. Natl Vital Stat Rep 56 (2008) 1-120
13. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 suppl (2007) S27-S72
14. Menendez R., Torres A., Zalacain R., et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 172 (2005) 757-762
15. Marrie T.J., Lau C.Y., Wheeler S.L., Wong C.J., Vandervoort M.K., Feagan B.G., and CAPITAL Study Investigators. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 283 (2000) 749-755
16. Menendez R., Ferrando D., Valles J.M., and Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest 122 (2002) 612-617
17. Fine M.J., Stone R.A., Lave J.R., et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med 115 (2003) 343-351
18. Capelastegui A., Espana P.P., Quintana J.M., et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 39 (2004) 955-963
19. Mortensen E.M., Restrepo M., Anzueto A., and Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 117 (2004) 726-731
20. Marrie T.J., and Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 127 (2005) 1260-1270
21. Frei C.R., Restrepo M.I., Mortensen E.M., and Burgess D.S. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 119 (2006) 865-871
22. Reyes Calzada S., Martinez Tomas R., Cremades Romero M.J., Martinez M.E., Soler C.J.J., and Menéndez V.R. Empiric treatment in hospitalized community-acquired pneumonia: impact on mortality, length of stay and re-admission. Respir Med 101 (2007) 1909-1915
23. Frei C.R., Koeller J.M., Burgess D.S., Talbert R.L., and Johnsrud M.T. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. Pharmacotherapy 23 (2003) 1167-1174
24. Lodise T.P., Kwa A., Cosler L., Gupta R., and Smith R.P. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 51 (2007) 3977-3982
25. Schein J., Janagap-Benson C., Grant R., Sikirica V., Doshi D., and Olson W. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Curr Med Res Opin 24 (2008) 895-906
26. Menendez R., Reyes S., Martinez R., de la Cuadra P., Manuel V.J., and Vallterra J. Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia. Eur Respir J 29 (2007) 751-756
27. Vardakas K.M., Siempos I.M., Grammatikos A.M., Athanassa Z., Korbilia I.P., and Falagas M.F. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 179 (2008) 1269-1277
28. Arnold F.W., Lajoie A.S., Brock G.N., et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 169 (2009) 1515-1524
29. Frei C.R., Jaso T.C., Mortensen E.M., et al. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Curr Med Res Opin 25 (2009) 859-868
30. DeFrances C.J., Cullen K.A., and Kozak L.J. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 (2007) 1-209
31. Colice G.L., Morley M.A., Asche C., and Birnbaum H.G. Treatment costs of community-acquired pneumonia in an employed population. Chest 125 (2004) 2140-2145
32. Raut M., Schein J., Mody S., Grant R., Benson C., and Olson W. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin 25 (2009) 2151-2157
33. Birnbaum H.G., Morley M., Greenberg P.E., Cifaldi M., and Colice G.L. Economic burden of pneumonia in an employed population. Arch Intern Med 161 (2001) 2725-2731
34. US Census Bureau Population Division. Table 1: annual estimates of the population for the United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2007 (NST-EST2007-01). 2007. [US Census Bureau Website.]. http://www.census.gov/popest/states/tables/NST-EST2007-01.xls Accessed April 17, 2009
35. Anzueto A., Niederman M.S., Pearle J., et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 42 (2006) 73-81
36. Lelekis M., and Gould I.M. Sequential antibiotic therapy for cost containment in the hospital setting: why not?. J Hosp Infect 48 (2001) 249-257
37. Wong-Beringer A., Nguyen K.H., and Razeghi J. Implementing a program for switching from i.v. to oral antimicrobial therapy. Am J Health Syst Pharm 58 (2001) 1146-1149
38. Athanassa Z., Makris G., Dimopoulos G., and Falagas M.E. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 68 (2008) 2469-2481
39. Siegel R.E., Halpern N.A., Almenoff P.L., Lee A., Cashin R., and Greene J.G. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia: the optimal duration of therapy. Chest 110 (1996) 965-971
40. Oosterheert J.J., Bonten M.J., Schneider M.M., et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 333 (2006) 1193
41. Omidvari K., de Boisblanc B.P., Karam G., Nelson S., Haponik E., and Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 92 (1998) 1032-1039
42. Norrby S.R., Petermann W., Willcox P.A., Vetter N., and Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 30 (1998) 397-404
43. Yaqub A., and Khan Z. Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community acquired pneumonia. Pak J Med Sci 21 (2005) 259-266
44. Castro-Guardiola A., Viejo-Rodriguez A.L., Soler-Simon S., et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 111 (2001) 367-374
45. Kuti J.L., Le T.N., Nightingale C.H., Nicolau D.P., and Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. Am J Health Syst Pharm 59 (2002) 2209-2215
46. Davis S.L., Delgado Jr. G., and McKinnon P.S. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 41 suppl 2 (2005) S136-S143
47. Wasserfallen J.B., Erard V., Cometta A., Calandra T., and Lamy O. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur Respir J 24 (2004) 644-648
48. Lode H., File Jr. T.M., Mandell L., Ball P., Pypstra R., Thomas M., and 185 Gemifloxacin Study Group. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 24 (2002) 1915-1936
49. Ye X., Sikirica V., Schein J.R., et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 30 (2008) 358-371
50. van Zanten A.R., Engelfriet P.M., van Dillen K., van Veen M., Nuijten M.J., and Polderman K.H. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care 7 (2003) R184-R190
51. Shehab N., Patel P.R., Srinivasan A., and Budnitz D.S. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 47 (2008) 735-743
52. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42 suppl 2 (2006) S82-S89